Insider buying last 90 days
No open-market insider purchases were filed for GPCR in the last 90 days.
From Form 4 filings, dated to when each was filed.
Every GPCR insider filing, plotted on the chart in Gekko.Open GPCR in Gekko
Structure Therapeutics (GPCR) Stock Analysis & Forecast
Oct 12 close
$23.91−1.63 (−6.4%)
Gekko Brief
AI summaryOct 12 closeStructure Therapeutics continues to trade under heavy pressure, with volatility tools flagging weak sentiment across all time horizons and a short bias on the stock. Shares touched a fresh 52-week low of $25.56 before easing further, a move described as a 62% year-to-date decline, though commentary around that low pointed to analysis suggesting the stock is undervalued and oversold, with recent updates from Jefferies, Citizens and H.C. noted alongside it.
GPCR closed at $23.91, down 6.4% on the day, sitting well below both its 50-day average of $42.03 and 200-day average of $52.38, with the 50-day also under the 200-day. One, three and six-month returns stand at -38.2%, -52.7% and -55.9% respectively, against a typical daily move of 7.5% and a typical 20-day move of 14.2%. The GekkoIndex reads 73.5, placing the stock in the Buying zone, down 2.3 over five days. Price sits 46.8% below the Gekko Fair Value of $44.95.
Earnings are due 5 November 2026, 23 days out and inside a typical 20-trading-day holding window; the last report on 6 August showed a loss of $0.49 versus a $0.39 estimate, with a 5.2% reaction, and 3 beats in 8 quarters logged. No insider, Congress or unusual options activity appears in the respective 90-day and 30-day windows. Seasonally, the next 20 trading days have averaged +6.3% over 3 years, rising in 2 of them. Analyst coverage from 14 firms is unanimously rated buy, with a consensus target of $105.78.
Written by AI from the Oct 12, 2026 close and checked automatically against the figures on this page.
Structure Therapeutics price vs fair value
Close $23.91200-day averageGekko Fair Value $44.95
Structure Therapeutics quick facts
- Market cap
- $1.38B
- P/E ratio
- —
- Forward P/E
- —
- EPS, TTM
- −$3.03
- Revenue, TTM
- $0
- Profit margin
- 0%
- Dividend yield
- —
- Beta
- -1.37
- Volume
- 1.65M avg 1.22M
- 1-year return
- −21.7%
- Typical daily move
- ±7.5%
- Typical 20-day move
- ±14.2%
- 50-day average
- $42.03
- 200-day average
- $52.38
- Next earnings
- Nov 5
- Shares outstanding
- 71.31M
Structure Therapeutics swing-trade checklist
Structure Therapeutics scores 3 supportive, 0 mixed and 2 headwinds across the 5 checklist items with data.
Six things swing traders check before a 20-day hold, read from the latest data.
3 supportive0 mixed2 headwinds
- Trendheadwind
Below 50 and 200-day
Close $23.91 is below the 50-day ($42.03) and 200-day ($52.38) averages, and the 50-day is below the 200-day.
See the chart - GekkoIndexsupportive
73.5, Buying
Reading 73.5 is in the Buying zone.
See the GekkoIndex - Fair valuesupportive
46.8% below
Price is 46.8% below Gekko Fair Value (more than 5% below).
See fair value - Smart moneyno data
No data
No insider, Congress or unusual options activity in the window.
See smart money - Earnings riskheadwind
Reports in 24 days
Reports on Nov 5, 2026, 24 days away — inside a typical 20-trading-day hold.
See earnings - Seasonalitysupportive
+6.3% on average
From this point in the calendar, the next 20 trading days averaged +6.3% over 3 years, rising in 2 of them.
See seasonality
A description of current data, not a recommendation. How this page works
Structure Therapeutics stock chart and price history
Structure Therapeutics closed at $23.91 on Oct 12, 2026, −21.7% over the past year, inside a 52-week range of $23.89 to $94.90.
Close50-day average200-day averageVolume
Use the left and right arrow keys to read daily values.
Performance Breakdown
- 1 month
- −38.2%
- 3 months
- −52.7%
- 6 months
- −55.9%
- 1 year
- −21.7%
The full GPCR chart adds GekkoIndex, insider, options, Congress and hedge fund markers, plus TrendCandles™.Open GPCR in Gekko
Follow Structure Therapeutics through every session
Put GPCR on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.
Track GPCR in GekkoFree for 7 days. No credit card required.
About Structure Therapeutics
Structure Therapeutics works in clinical-stage biopharmaceutical research, focused on developing oral medicines for chronic illnesses that currently have few effective treatments. Its best-known program centers on GSBR-1290, a small molecule taken by mouth that acts on the glucagon-like-peptide-1 receptor, a target already used in treating type-2 diabetes and obesity.
Beyond this lead program, the company is advancing additional oral compounds aimed at other receptors in the same family. ANPA-0073 targets the apelin receptor and is being studied for conditions such as idiopathic pulmonary fibrosis and pulmonary arterial hypertension, while LTSE-2578 works against the lysophosphatidic acid 1 receptor and is also being explored for pulmonary fibrosis. Together these programs span treatments aimed at metabolic, pulmonary and cardiovascular disease.
The company was founded in 2016 under the name ShouTi Inc. and is based in South San Francisco, California. Its shares trade under the ticker GPCR.
- Sector
- Health technology
- Website
- structuretx.com
Structure Therapeutics GekkoIndex: the smart money zone
Structure Therapeutics’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 73.5, in the Buying zone, down 2.3 points over five sessions.
73.5Buying
Down 2.3 points over five sessions.
Reading for Oct 12, 2026
What followed past readings in each zone
| Zone | Readings | 5 days | 20 days | ||
|---|---|---|---|---|---|
| Buying (current zone) | 61 | +0.8% | +11.1% | ||
| Accumulation | 265 | −1.0% | −3.9% | ||
| Neutral | 278 | +2.0% | +7.5% | ||
| Distribution | 30 | −2.2% | −5.9% | ||
| Selling | 1 | Too few readings yet | |||
Average GPCR share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Buying readings averaged +3.1% over 20 days. Past behaviour doesn’t guarantee future results.
Buying zone: Smart money likely accumulating heavily. About the five zones →
See every daily GekkoIndex reading plotted over the GPCR price, zone by zone.Track GPCR in Gekko
Is Structure Therapeutics stock overvalued? Gekko Fair Value
Structure Therapeutics trades 46.8% below Gekko Fair Value of $44.95, so the shares are undervalued on Gekko’s estimate.
Gekko’s own estimate of what Structure Therapeutics shares are worth, recalculated every trading day.
$44.95
Gekko Fair Value, Oct 10, 2026
46.8% Undervalued
At the end of Aug 2026 the price was 19.9% below the estimate.
Gekko Fair ValueShare price, month end
Gekko Fair Value on every chart, with the gap to price updating daily.Open GPCR in Gekko
Structure Therapeutics insider and Congress trading
No open-market insider purchases were filed for Structure Therapeutics, and no Congress trades were disclosed, in the last 90 days.
Plus buybacks, unusual options and fund positions, each dated to when it became public.
Congress trades last 90 days
No trades in GPCR were disclosed by members of Congress in the last 90 days.
From congressional disclosures, which report amounts as ranges.
Congress disclosures for GPCR, plotted on the chart in Gekko.Open GPCR in Gekko
Buybacks
Structure Therapeutics has been buying back its own shares.
- Bought back, quarter ended Jun 30, 2022
- $6K
- As a share of market cap
- 0.00%
From company filings.
Hedge funds and billionaires quarter ended Mar 31
0of the funds Gekko tracks hold GPCR.
0added0opened0trimmed1sold out
Which funds are on each side, name by name.Unlock in Gekko
Structure Therapeutics earnings: next date and track record
Structure Therapeutics reports on Nov 5, 2026 (24 days away), and beat the EPS estimate in 3 of its last 8 reports.
Next earnings report
Nov 5, 2026
24 days away
- EPS estimate
- −$0.32
- Revenue estimate
- $50.00M
3 of 8reports beat the EPS estimate
±5.6%average move across the report
4 of 8reports followed by a gain
Share-price move across each report
| Reported | EPS | Revenue | Move |
|---|---|---|---|
| Aug 6, 2026 | −$0.49 est −$0.39 | — | +5.2% |
| May 7, 2026 | −$0.35 est −$0.35 | — est $11.11M | −4.3% |
| Feb 26, 2026 | $0.20 est −$0.28 | — est $9.19M | −5.3% |
| Nov 6, 2025 | −$0.37 est −$0.36 | — | +2.0% |
| Aug 6, 2025 | −$0.36 est −$0.28 | — | −2.9% |
| May 8, 2025 | −$0.27 est −$0.24 | — | −3.9% |
| Feb 27, 2025 | −$0.21 est −$0.28 | $1.78M | +19.5% |
| Nov 13, 2024 | −$0.20 est −$0.27 | — | +1.9% |
“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.
Structure Therapeutics stock forecast and analyst price targets
Analysts’ average 12-month price target for Structure Therapeutics is $105.78, +342.4% from the last close, from 14 firms rating the stock in the last 90 days.
$105.78consensus 12-month target, +342.4% from the last close
Now $23.91Avg $105.78
Low $70High $145
Each firm’s latest rating in the last 90 days: 14 firms.
Latest analyst actions
| Date | Firm | Target | vs price |
|---|---|---|---|
| Sep 9 | Canaccord Genuity | $111 | +364.2% |
| Sep 9 | H.C. Wainwright | $70 | +192.8% |
| Sep 9 | H.C. Wainwright | $70 | +192.8% |
| Sep 8 | Jefferies | $125 | +422.8% |
| Sep 8 | LifeSci Capital | $104 | +335.0% |
+11.1%average 20-day move after past Buying readings
+6.3%average move over the next 20 trading days in the last 3 years
±7.5%typical daily move, from the 14-day average range
Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.
Structure Therapeutics seasonality: the next 20 trading days
Over the next 20 trading days from Oct 10, Structure Therapeutics averaged +6.3% across the last 3 years, rising in 2 of them.
Next 20 trading days, by year
Average move and hit rate
| Window | Average | Years higher |
|---|---|---|
| Next 5 trading days | −2.3% | 1 of 3 |
| Next 10 trading days | −2.1% | 1 of 3 |
| Next 15 trading days | +8.4% | 2 of 3 |
| Next 20 trading days | +6.3% | 2 of 3 |
| Next 30 trading days | −7.1% | 1 of 3 |
For scale, GPCR’s typical 20-trading-day move in either direction is about 14.2%.
Structure Therapeutics market cap and key statistics
Structure Therapeutics’s market cap is $1.38B and revenue of $0 over the last twelve months.
Valuation
- Market cap
- $1.38B
- EPS, TTM
- −$3.03
- Gekko Fair Value
- $44.95
Trading
- Volume
- 1.65M
- Avg volume, 20 days
- 1.22M
- 52-week high
- $94.90
- 52-week low
- $23.89
- Shares outstanding
- 71.31M
Financials
- Revenue, TTM
- $0
- Profit margin
- 0%
- Return on equity
- -20.2%
- Quarterly earnings growth, YoY
- 0.0%
Risk and income
- Beta
- -1.37
- Typical daily move
- ±7.5%
- Typical 20-day move
- ±14.2%
Structure Therapeutics stock news this week
2 headlines about Structure Therapeutics from the past week, newest first, each linking to the publisher.
- Trading Systems Reacting to (GPCR) VolatilityStock Traders Daily, Oct 12
- Structure Therapeutics stock hits 52-week low at 25.56 USD By Investing.comInvesting.com Nigeria, Oct 8
Structure Therapeutics stock FAQ
What is Structure Therapeutics’s market cap?
Structure Therapeutics’s market cap is $1.38B at the Oct 12, 2026 close of $23.91, with 71.31M shares outstanding.
What is the Structure Therapeutics stock forecast?
The consensus analyst 12-month price target for Structure Therapeutics is $105.78, +342.4% from the last close. Of the 14 firms that rated the stock in the last 90 days, 14 rate it a buy, 0 a hold and 0 a sell. Gekko doesn’t publish price predictions of its own.
Is Structure Therapeutics stock overvalued or undervalued?
On Gekko’s estimate Structure Therapeutics is undervalued: the Oct 12, 2026 close of $23.91 is 46.8% below Gekko Fair Value of $44.95. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.
When does Structure Therapeutics report earnings next?
Structure Therapeutics is expected to report on Nov 5, 2026 (24 days away). Analysts expect earnings of −$0.32 per share on revenue of $50.00M. Structure Therapeutics beat the earnings estimate in 3 of its last 8 reports, moving 5.6% on average across the report.
What is Structure Therapeutics’s 52-week high and low?
Structure Therapeutics’s 52-week high is $94.90 and its 52-week low is $23.89; it closed at $23.91 on Oct 12, 2026, −21.7% over the past year.
Is Structure Therapeutics stock a buy right now?
Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 3 of the 5 items with data read as supportive (gekkoindex, fair value and seasonality) and 2 as headwinds (trend and earnings risk). The checklist is a description of current data, not a recommendation.
How this page works
During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →
See Structure Therapeutics the way Gekko members do
Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.
Join 1,408 other traders using Gekko
Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.